Advanced Urotheilal carcinoma - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Advanced Urothelial Carcinoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Advanced Urothelial Carcinoma: Overview
Urothelial carcinoma, also known as transitional cell carcinoma is the most common type of bladder cancer. This type of cancer starts in the urothelial cells of the urothelium lining of the bladder. These cells are also found in other parts of the urinary tract, such as the renal pelvis and, the urethra, and the ureters therefore, people with urothelial cancer may also have tumors in these parts as well. Urothelial carcinoma is the predominant histologic type in Europe and the United States where it accounts for about 90 percent of all bladder cancers. With disease progression, the cancer may metastasize and then it is referred to as advanced urothelial carcinoma.
“Advanced Urothelial Carcinoma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Urothelial Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Urothelial Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Urothelial Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Urothelial Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Urothelial Carcinoma.
Advanced Urothelial Carcinoma Emerging Drugs Chapters
This segment of the Advanced Urothelial Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Urothelial Carcinoma Emerging Drugs
Rogaratininb: Bayer
Bayer’s drug candidate rogaratinib is in the phase II/III stage of the drug development process. The drug molecule is an investigational fibroblast growth factor receptor (FGFR) inhibitor that has shown potential in inhibiting the pathway in preclinical studies. The drug molecule has shown to be prevent both ligand-dependent and independent FGFR activation.
Sitravatinib: Mirati Therapeutics, Inc
Mirati Therapeutics’s drug candidate Sitravatinib, is a multitargeted tyrosine kinase inhibitor which is being tested for NSCLC as well as advanced urothelial carcinoma. For the latter indication, the drug is being evaluated in phase II trial where its effect is being tested as an orally administered drug to be given in combination with nivolumab.
Further product details are provided in the report……..
Advanced Urothelial Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Urothelial Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Advanced Urothelial Carcinoma
There are approx. 4+ key companies which are developing the therapies for Advanced Urothelial Carcinoma. The companies which have their Advanced Urothelial Carcinoma drug candidates in the most advanced stage, i.e. phase II include, Bayer.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Advanced Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Advanced Urothelial Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Urothelial Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Urothelial Carcinoma drugs.
Advanced Urothelial Carcinoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Advanced Urothelial Carcinoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Advanced Urothelial Carcinoma: Overview
Urothelial carcinoma, also known as transitional cell carcinoma is the most common type of bladder cancer. This type of cancer starts in the urothelial cells of the urothelium lining of the bladder. These cells are also found in other parts of the urinary tract, such as the renal pelvis and, the urethra, and the ureters therefore, people with urothelial cancer may also have tumors in these parts as well. Urothelial carcinoma is the predominant histologic type in Europe and the United States where it accounts for about 90 percent of all bladder cancers. With disease progression, the cancer may metastasize and then it is referred to as advanced urothelial carcinoma.
“Advanced Urothelial Carcinoma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Urothelial Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Urothelial Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Urothelial Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Urothelial Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Urothelial Carcinoma.
Advanced Urothelial Carcinoma Emerging Drugs Chapters
This segment of the Advanced Urothelial Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Urothelial Carcinoma Emerging Drugs
Rogaratininb: Bayer
Bayer’s drug candidate rogaratinib is in the phase II/III stage of the drug development process. The drug molecule is an investigational fibroblast growth factor receptor (FGFR) inhibitor that has shown potential in inhibiting the pathway in preclinical studies. The drug molecule has shown to be prevent both ligand-dependent and independent FGFR activation.
Sitravatinib: Mirati Therapeutics, Inc
Mirati Therapeutics’s drug candidate Sitravatinib, is a multitargeted tyrosine kinase inhibitor which is being tested for NSCLC as well as advanced urothelial carcinoma. For the latter indication, the drug is being evaluated in phase II trial where its effect is being tested as an orally administered drug to be given in combination with nivolumab.
Further product details are provided in the report……..
Advanced Urothelial Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Urothelial Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Advanced Urothelial Carcinoma
There are approx. 4+ key companies which are developing the therapies for Advanced Urothelial Carcinoma. The companies which have their Advanced Urothelial Carcinoma drug candidates in the most advanced stage, i.e. phase II include, Bayer.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Advanced Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intramuscular
- Subcutaneous
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Advanced Urothelial Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Urothelial Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Urothelial Carcinoma drugs.
Advanced Urothelial Carcinoma Report Insights
- Advanced Urothelial Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Urothelial Carcinoma drugs?
- How many Advanced Urothelial Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Urothelial Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Urothelial Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Urothelial Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bayer
- Mirati Therapeutics
- Rogaratininb
- Sitravatinib
Introduction
Executive Summary
Advanced Urothelial Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Urothelial Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Advanced Urothelial Carcinoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Advanced Urothelial Carcinoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Rogaratininb: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Advanced Urothelial Carcinoma Key Companies
Advanced Urothelial Carcinoma Key Products
Advanced Urothelial Carcinoma- Unmet Needs
Advanced Urothelial Carcinoma- Market Drivers and Barriers
Advanced Urothelial Carcinoma- Future Perspectives and Conclusion
Advanced Urothelial Carcinoma Analyst Views
Advanced Urothelial Carcinoma Key Companies
Appendix
Executive Summary
Advanced Urothelial Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Urothelial Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Advanced Urothelial Carcinoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Advanced Urothelial Carcinoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Rogaratininb: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Advanced Urothelial Carcinoma Key Companies
Advanced Urothelial Carcinoma Key Products
Advanced Urothelial Carcinoma- Unmet Needs
Advanced Urothelial Carcinoma- Market Drivers and Barriers
Advanced Urothelial Carcinoma- Future Perspectives and Conclusion
Advanced Urothelial Carcinoma Analyst Views
Advanced Urothelial Carcinoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Advanced Urothelial Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Advanced Urothelial Carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Advanced Urothelial Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Advanced Urothelial Carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
